Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Recruiting now · Phase 1
Conditions studied: Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus Erythematosus (CLE), Atopic Dermatitis (AD)
In brief
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).
Key facts
- Study ID
- NCT07455578
- Run by
- Seismic Therapeutic AU Pty Ltd
- People needed
- 24
- Starts
- 2026-06-01
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novatrials — Charlestown, New South Wales, Australia (enrolling)
- University of the Sunshine Coast Clinical Trials, Birtinya — Birtinya, Queensland, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.